#ESMO26 Presidential 1:
As Tarlatamab moves from the 2L to the 1L setting, it suddenly becomes taller 😄😄
Congrats @sands_jacob , we are here to celebrate with you for the dawn of a new era for our patients with #SCLC
@myESMO @SclcSMASHERS @StephenVLiu
161 views · 7 likes · 1 repost · 0 replies
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Giannis Mountzios · x.com